Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
1998-02-01
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer
cells from dividing so they stop growing or die. Combining more than one drug may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating
patients who have relapsed low-grade non-Hodgkin's lymphoma.
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Completed
Alliance for Clinical Trials in Oncology
Phase 2
1998-02-01
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer
cells from dividing so they stop growing or die. Combining more than one drug may kill more
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating
patients who have relapsed low-grade non-Hodgkin's lymphoma.
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Completed
NCIC Clinical Trials Group
Phase 3
1996-09-24
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of
estrogen. It is not yet known which treatment regimen is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without
octreotide in treating postmenopausal women who have stage I, stage II, or stage III breast
cancer.
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Completed
Cancer and Leukemia Group B
Phase 3
1996-11-01
RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to
relieve the diarrhea caused by chemotherapy.
PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with
loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who
have colorectal cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
